Tumors were reduced on bone scans, bone pain decreased after patients received cabozantinib
Written by Nicole Fawcett.
ANN ARBOR, Mich. - A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a study reported by University of Michigan Comprehensive Cancer Center researchers.
A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for prostate cancer.
Xofigo, a newly approved treatment for advanced prostate cancer, delivers a powerful punch of radiation directly to tumor cells that have invaded the bone.